What do the blends contain as labeled?

GLOW’s labeled vial composition is GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg (product page glow). KLOW’s labeled vial composition is GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg + KPV 10mg (product page klow). These are product-documentation statements, not analytical measurements.

What does preclinical tolerability establish?

The “no signs of toxicity” statement concerns KPV/FK506 nanoparticles in mice after intravenous exposure for 7 days (PMID 39211778). The systemic-toxicity statement concerns orally administered proKPV conjugate in mice over 7 days (PMID 41533788). Neither statement belongs to free KPV.

How much copper does the labeled composition imply, and which reference values apply?

Computed from copper at 63.55 g/mol and the cation at 402.92 g/mol: labeled 50 mg GHK-Cu × 63.55 / 402.92 = 7.89 mg elemental copper per GLOW or KLOW vial (product pages glow/klow; PubChem CID 23978; CID 71587328). Counter-ions and water can alter powder composition. EFSA’s adult oral ADI is 0.07 mg/kg bw per day, equivalent to 5 mg Cu/day (EFSA 2023 scientific opinion, PMID 36694841); IOM’s adult oral UL is 10,000 microgram/day (10 mg/day) (IOM 2001). These are oral values, not parenteral thresholds.

What do the community counts represent?

66 of 1,692 question posts mention the glow-klow-kpv regex and a redness/welt/hive/itch term within 250 characters (corpus 12 months, 2025-08-01 to 2026-09-04). Separately, 1 of 111 question posts meet that definition in the delta, 2026-09-04 to 2026-09-12 (corpus delta). These are mentions, not rates; denials also match.

Which sources address sting and redness?

The quantified scalp-injection pain finding concerns a multi-ingredient cocktail plus oral/topical therapy (PMID 30057663). The topical post-laser study measured erythema resolution (PMID 16847171). Neither endpoint is a blend-specific sting or wheal measurement.

Where do the numbers come from?

The article draws on corpus counts, publication findings, posted registry rows, regulatory documents, product-page labels and PubChem-based arithmetic. Each figure retains its source, arm, route and window. A labeled mass is not an analytical result.

What do the component articles cover?

The GHK-Cu article details topical studies, cosmetic derivative tests, cocktails and documented reporting gaps. The BPC-157/TB-500 article separates pilots and FDA reports from full-length thymosin beta-4 studies by route and the fragment’s absence searches.

GLOW/KLOW/KPV Side Effects: 66 Skin-Term Mentions, 0 KPV Blend Studies

Q: What does the hypersensitivity record contain?

CIR’s human sensitization testing concerns palmitoyl-GHK trade material, not copper tripeptide-1 (CIR safety assessment 2014). Full-length thymosin beta-4 topical gel recorded hypersensitivity 1/53 versus placebo 0/18 (NCT00382174). As of 2026-09-13, no completed study has reported dedicated KPV toxicology covering acute toxicity, repeat-dose testing, genotoxicity or dermal sensitization (PubMed search: '("KPV"[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (toxicology[tiab] OR "LD50"[tiab] OR genotoxicity[tiab] OR "repeated dose"[tiab] OR "repeat-dose"[tiab] OR sensitization[tiab] OR sensitisation[tiab])', 1 hit; ClinicalTrials.gov search: 'KPV', 0 records).

Q: What does the FDA category-2 listing say?

The KPV row sits under withdrawn nominations previously in category 2. FDA states: “FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration.” (FDA bulk drug substances page).

The headline counts mentions (corpus 12 months). The blend search below covers KPV with other components, not GLOW without KPV.

GLOW’s labeled composition per vial is “GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg, research-grade blend (70mg total)” (product page glow). KLOW’s is “GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg + KPV 10mg (80mg total)” (product page klow). KPV is Lys-Pro-Val, residues 11-13 of alpha-MSH (product page kpv).

This report compares question-post counts with studies and regulatory documents. Mentions are not adverse-event evidence. Component details appear in the GHK-Cu article and BPC-157/TB-500 article.

GLOW, KLOW and KPV are listed at PeptidesDirect as research-grade products.

GLOWregeneration

GLOW is a co-lyophilized vial holding GHK-Cu, BPC-157 and TB-500 at a fixed 50:10:10 mass ratio, 70 mg total. Each peptide has its own published literature; no study has tested the three together. Per-component content on the batch CoA.

KLOWregeneration

KLOW is a co-lyophilized vial holding GHK-Cu, BPC-157, TB-500 and KPV at a fixed 50:10:10:10 mass ratio, 80 mg total. Each peptide has its own published literature; no study has tested the four together. Per-component content on the batch CoA.

What research communities ask about

Reddit’s “12 months” window spans 2025-08-01 to 2026-09-04 (corpus 12 months); the separate delta spans 2026-09-04 to 2026-09-12 (corpus delta). Dates use fixed corpus labels for the longer window and UTC timestamps for delta; subreddit sets differ.

Method: title plus body is matched case-insensitively with these compound regexes (corpus method):

GLOW: \bglow\b(?!\s*(up|ing|y))
KLOW: \bklow\b
KPV: \bkpv\b
Any: \bglow\b(?!\s*(up|ing|y))|\bklow\b|\bkpv\b

Deduplication retains the first post ID; delta excludes seen IDs. Category-match starts must lie within 250 characters of compound-match starts (corpus method). Bare “glow” also matches the ordinary word. “Any” deduplicates across names. Windows are never added. Questions, reports and denials match without interpreting negation or causality.

Cells mean “N of M question posts mention the column’s regex label and category term within 250 characters” (corpus method).

Category	GLOW (12 months)	KLOW (12 months)	KPV (12 months)	Any of the three (12 months)	Any (delta)	Meaning of matched terms
redness/welt/hive/itch	20 of 723	29 of 741	26 of 427	66 of 1,692	1 of 111	Red marks, rash, wheals
sting/burn	34 of 723	21 of 741	11 of 427	61 of 1,692	3 of 111	Stinging, burning
fatigue/tired	12 of 723	14 of 741	15 of 427	38 of 1,692	2 of 111	Tiredness, lethargy
pain at site	18 of 723	18 of 741	7 of 427	34 of 1,692	5 of 111	Soreness, hurts
zinc	8 of 723	11 of 741	8 of 427	23 of 1,692	0 of 111	Zinc
lump/bump/nodule	6 of 723	11 of 741	2 of 427	19 of 1,692	4 of 111	Knots, hard spots
allergy/anaphylaxis	6 of 723	6 of 741	6 of 427	16 of 1,692	0 of 111	Allergic terminology
water retention	4 of 723	4 of 741	8 of 427	15 of 1,692	1 of 111	Bloating, puffiness
bruise	5 of 723	3 of 741	3 of 427	11 of 1,692	2 of 111	Bruising
swelling	0 of 723	5 of 741	6 of 427	10 of 1,692	0 of 111	Swollen, edema
nausea	5 of 723	2 of 741	3 of 427	10 of 1,692	1 of 111	Nausea, vomiting
dizziness/BP	1 of 723	7 of 741	3 of 427	10 of 1,692	0 of 111	Lightheadedness, blood pressure
hair shedding	6 of 723	3 of 741	1 of 427	10 of 1,692	1 of 111	Hair-loss terminology
infection/abscess	3 of 723	1 of 741	5 of 427	8 of 1,692	0 of 111	Infection terminology
headache	2 of 723	0 of 741	5 of 427	7 of 1,692	0 of 111	Headache, migraine
insomnia/drowsy	2 of 723	0 of 741	1 of 427	3 of 1,692	0 of 111	Sleeplessness, drowsiness
copper toxicity	2 of 723	1 of 741	0 of 427	3 of 1,692	0 of 111	Copper terms or “toxic”

redness/welt/hive/itch

GLOW (12 months): 20 of 723
KLOW (12 months): 29 of 741
KPV (12 months): 26 of 427
Any of the three (12 months): 66 of 1,692
Any (delta): 1 of 111
Meaning of matched terms: Red marks, rash, wheals

sting/burn

GLOW (12 months): 34 of 723
KLOW (12 months): 21 of 741
KPV (12 months): 11 of 427
Any of the three (12 months): 61 of 1,692
Any (delta): 3 of 111
Meaning of matched terms: Stinging, burning

fatigue/tired

GLOW (12 months): 12 of 723
KLOW (12 months): 14 of 741
KPV (12 months): 15 of 427
Any of the three (12 months): 38 of 1,692
Any (delta): 2 of 111
Meaning of matched terms: Tiredness, lethargy

pain at site

GLOW (12 months): 18 of 723
KLOW (12 months): 18 of 741
KPV (12 months): 7 of 427
Any of the three (12 months): 34 of 1,692
Any (delta): 5 of 111
Meaning of matched terms: Soreness, hurts

zinc

GLOW (12 months): 8 of 723
KLOW (12 months): 11 of 741
KPV (12 months): 8 of 427
Any of the three (12 months): 23 of 1,692
Any (delta): 0 of 111
Meaning of matched terms: Zinc

lump/bump/nodule

GLOW (12 months): 6 of 723
KLOW (12 months): 11 of 741
KPV (12 months): 2 of 427
Any of the three (12 months): 19 of 1,692
Any (delta): 4 of 111
Meaning of matched terms: Knots, hard spots

allergy/anaphylaxis

GLOW (12 months): 6 of 723
KLOW (12 months): 6 of 741
KPV (12 months): 6 of 427
Any of the three (12 months): 16 of 1,692
Any (delta): 0 of 111
Meaning of matched terms: Allergic terminology

water retention

GLOW (12 months): 4 of 723
KLOW (12 months): 4 of 741
KPV (12 months): 8 of 427
Any of the three (12 months): 15 of 1,692
Any (delta): 1 of 111
Meaning of matched terms: Bloating, puffiness

bruise

GLOW (12 months): 5 of 723
KLOW (12 months): 3 of 741
KPV (12 months): 3 of 427
Any of the three (12 months): 11 of 1,692
Any (delta): 2 of 111
Meaning of matched terms: Bruising

swelling

GLOW (12 months): 0 of 723
KLOW (12 months): 5 of 741
KPV (12 months): 6 of 427
Any of the three (12 months): 10 of 1,692
Any (delta): 0 of 111
Meaning of matched terms: Swollen, edema

nausea

GLOW (12 months): 5 of 723
KLOW (12 months): 2 of 741
KPV (12 months): 3 of 427
Any of the three (12 months): 10 of 1,692
Any (delta): 1 of 111
Meaning of matched terms: Nausea, vomiting

dizziness/BP

GLOW (12 months): 1 of 723
KLOW (12 months): 7 of 741
KPV (12 months): 3 of 427
Any of the three (12 months): 10 of 1,692
Any (delta): 0 of 111
Meaning of matched terms: Lightheadedness, blood pressure

hair shedding

GLOW (12 months): 6 of 723
KLOW (12 months): 3 of 741
KPV (12 months): 1 of 427
Any of the three (12 months): 10 of 1,692
Any (delta): 1 of 111
Meaning of matched terms: Hair-loss terminology

infection/abscess

GLOW (12 months): 3 of 723
KLOW (12 months): 1 of 741
KPV (12 months): 5 of 427
Any of the three (12 months): 8 of 1,692
Any (delta): 0 of 111
Meaning of matched terms: Infection terminology

headache

GLOW (12 months): 2 of 723
KLOW (12 months): 0 of 741
KPV (12 months): 5 of 427
Any of the three (12 months): 7 of 1,692
Any (delta): 0 of 111
Meaning of matched terms: Headache, migraine

insomnia/drowsy

GLOW (12 months): 2 of 723
KLOW (12 months): 0 of 741
KPV (12 months): 1 of 427
Any of the three (12 months): 3 of 1,692
Any (delta): 0 of 111
Meaning of matched terms: Sleeplessness, drowsiness

copper toxicity

GLOW (12 months): 2 of 723
KLOW (12 months): 1 of 741
KPV (12 months): 0 of 427
Any of the three (12 months): 3 of 1,692
Any (delta): 0 of 111
Meaning of matched terms: Copper terms or “toxic”

Column sources: corpus 12 months; corpus delta. Leading categories are redness/welt/hive/itch, sting/burn and fatigue/tired in the longer window; site pain, lumps and sting/burn in delta (corpus counts). Mentions establish neither incidence nor whether reactions occur.

What is known per component

GHK-Cu: the topical post-laser study assessed erythema resolution (PMID 16847171). Scalp-injection studies tested multi-ingredient cocktails, precluding GHK-Cu-specific attribution (PMID 30057663; PMID 29482481). CIR human tests concern palmitoyl-GHK trade material, not copper tripeptide-1 (CIR safety assessment 2014). Arm-level adverse-event-table and single-agent gaps are documented in the GHK-Cu article.

BPC-157: FDA retrieved three FAERS reports concerning injectable BPC-157 through December 4, 2025, without an exposure denominator (FDA PCAC briefing, fda.gov/media/193343). Computed participant ratios were 0/2 with reported side effects over the intravenous pilot’s 3-day study (PMID 40131143), and 0/12 with adverse events after the intravesical pilot’s single procedure, follow-up unstated (PMID 39325560). The randomized-readout gap is documented in the component article.

TB-500: analytical identification found Ac-LKKTETQ, the N-acetylated 17-23 fragment of thymosin beta-4 (PMID 22962027). Human trial rows concern full-length thymosin beta-4 intravenously (PMID 34346165), topically in the eye (NCT03937882) or as topical gel (NCT00832091), not that fragment. The human-fragment gap is documented in the component article.

KPV: what the record contains

As of 2026-09-13, no completed study has reported safety, tolerability or adverse-event data for KPV in humans by any route (PubMed search: '("KPV"[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab] OR "alpha-MSH(11-13)"[tiab]) AND (patients[tiab] OR volunteers[tiab] OR "healthy subjects"[tiab] OR "clinical trial"[pt] OR "randomized controlled trial"[pt] OR "phase 1"[tiab])', 9 hits, none a human administration study; ClinicalTrials.gov search: 'KPV', 0 records).

The FDA’s bulk-substances table states: “This list of bulk drug substances previously in category 2 of the interim policies were withdrawn by the nominators.” Its KPV row reads: “FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration. FDA lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans.” This concerns withdrawn 503A/503B nominations (FDA bulk drug substances page).

Free-KPV mouse study arms used 1 mg/kg intraperitoneally once with 24 h observation (PMID 23940690), 1 mg/kg per day intravenously for 7 days (PMID 39211778), and 1 mg/kg orally daily for 7 days (PMID 41533788). The table below keeps their observations separate from nanoparticle and conjugate histology.

For the immune-suppression question, the source reports a dose-dependent inhibition of NF-kappaB, matrix metalloproteinase-9 activity, IL8 and eotaxin secretion in a human bronchial epithelial cell line in vitro, printed for KPV and gamma-MSH (PMID 22837805). Ex-vivo blood cytokine reduction was attributed collectively to melanocortins (PMID 9700761); enhanced killing by isolated neutrophils likewise concerns “alpha-MSH peptides” collectively (PMID 10670585). These are mechanism findings.

As of 2026-09-13, no completed study has reported infection rates or immune-competence endpoints in intact animals or humans under KPV (PubMed search: '("KPV"[tiab] OR "Lys-Pro-Val"[tiab] OR "alpha-MSH(11-13)"[tiab]) AND (infection[tiab] OR sepsis[tiab] OR immunosuppression[tiab] OR immunocompromised[tiab] OR "host defense"[tiab] OR "host defence"[tiab] OR "bacterial clearance"[tiab])', 10 hits; ClinicalTrials.gov search: 'KPV immune', 0 records).

Oral KPV in APCMin/+ mice at 100 micromol/L in drinking water for 13 weeks yielded (PMID 27458604): “KPV did not decrease the tumor burden in the small intestine or in the colon.” The paper prints no statement of an increase; this is not a carcinogenicity assessment (PMID 27458604).

Does KPV tan or flush like alpha-MSH?

The lizard-skin bioassay identified melanotropic agonism’s minimal sequence as residues 6-9; KPV itself was not tested (PMID 2537778). KPV occupies residues 11-13 of alpha-MSH (product page kpv), the fragment the study names alpha-MSH(11-13) (PMID 23940690). The mouse intraperitoneal study states “without melanotropic side effects of the complete functional protein”; this author statement accompanies a 24 h brain-injury experiment without pigmentation measurements (PMID 23940690). Structure-activity data do not measure flushing.

As of 2026-09-13, no completed study has reported skin or coat pigmentation measurements in living mammals administered KPV alone (PubMed search: '("KPV"[tiab] OR "alpha-MSH(11-13)"[tiab] OR "Lys-Pro-Val"[tiab]) AND (pigmentation[tiab] OR melanogenesis[tiab] OR melanin[tiab] OR tanning[tiab] OR melanotropic[tiab])', 13 hits; ClinicalTrials.gov search: 'KPV', 0 records).

Copper in the blends

Each vial is labeled with 50 mg GHK-Cu (product page glow; product page klow). Computed using copper’s 63.55 g/mol and the cation’s 402.92 g/mol, 63.55 / 402.92 = 0.1577, or 15.8 % copper by mass (PubChem CID 23978; CID 71587328). Per GLOW or KLOW vial, labeled 50 mg × 63.55 / 402.92 = 7.89 mg elemental copper (product pages glow/klow; PubChem CID 23978; CID 71587328). The 402.92 g/mol cation is C14H23CuN6O4+; counter-ions, protonation and water can alter the powder’s copper content, so the real copper per vial can differ by a few percent (computed from PubChem CID 71587328 and CID 23978). This is content, never a dose.

For adults’ oral intake from all sources, EFSA’s ADI is 0.07 mg/kg bw per day, equivalent to 5 mg Cu/day (EFSA 2023 scientific opinion, PMID 36694841). IOM’s adult oral UL is 10,000 microgram/day (10 mg/day) (IOM 2001). Both reference values are oral; neither body sets a parenteral copper-peptide limit in the retrieved documents. See the copper-arithmetic article.

Corpus question terms mapped to study sources

Sting/burn: the GHK-Cu sting article discusses mechanisms without a human sting measurement. The multi-ingredient scalp-injection cocktail plus oral/topical therapy recorded slight pain: 651/18918 patients over at least 6 months (PMID 30057663).

Redness/wheals/itch: topical post-laser erythema resolution showed “no statistically significant differences between groups” (PMID 16847171). Full-length thymosin beta-4 topical gel recorded pruritus 4/55 versus placebo 1/17, erythema 3/55 versus 0/17, and rash 2/55 versus 0/17 over 99 days; separate participant rows, active concentrations pooled (NCT00832091).

Lumps/nodules: the logged GHK-Cu nodule search of 2026-09-13 returned 2 PubMed hits and 3 ClinicalTrials.gov records, none describing nodules (GHK-Cu article). No posted registry table and neither phase 1 publication of BPC-157 or full-length thymosin beta-4 prints a lump or nodule term (BPC-157/TB-500 article).

Bruising: intravenous full-length thymosin beta-4 NL005 recorded puncture-site bruising: 1 event in 8 subjects versus 0 events in 6 placebo subjects, in the 2.0 ug/kg daily arm for 10 days, observed 28 days (PMID 34346165).

PeptidesDirect does not sell NL005.

Fatigue: full-length thymosin beta-4 topical gel recorded asthenia 1/53 versus placebo 0/18 in pressure-ulcer patients (NCT00382174). This cannot characterize injected exposure.

Hypersensitivity: palmitoyl-GHK trade-material testing reported no clinically significant sensitization in 52 subjects, not copper tripeptide-1 exposure (CIR safety assessment 2014). Full-length thymosin beta-4 topical gel recorded hypersensitivity 1/53 versus placebo 0/18 (NCT00382174).

Zinc: EFSA discusses oral zinc supplementation and copper status, not blends (EFSA 2023 scientific opinion, PMID 36694841).

Across the reaction groups above, the KPV reaction-rate search documents the following gap:

As of 2026-09-13, no completed study has reported KPV reaction rates for injection-site reactions, flushing, nausea, headache, hypersensitivity or blood-pressure changes (PubMed search: '("KPV"[tiab] OR "Lys-Pro-Val"[tiab] OR "alpha-MSH(11-13)"[tiab]) AND (pruritus[tiab] OR flushing[tiab] OR nausea[tiab] OR headache[tiab] OR hypersensitivity[tiab] OR "injection site"[tiab] OR "blood pressure"[tiab])', 1 hit; ClinicalTrials.gov search: 'KPV', 0 records).

What no trial has measured

As of 2026-09-13, no completed study has reported administration of KPV with BPC-157, TB-500 / thymosin beta-4 or GHK-Cu in any organism (PubMed search: '("KPV"[tiab] OR "Lys-Pro-Val"[tiab] OR "alpha-MSH(11-13)"[tiab]) AND ("BPC 157"[tiab] OR "BPC-157"[tiab] OR "TB-500"[tiab] OR "TB500"[tiab] OR "thymosin beta 4"[tiab] OR "thymosin beta-4"[tiab] OR "GHK-Cu"[tiab] OR "copper peptide"[tiab] OR "glycyl-histidyl-lysine"[tiab])', 0 hits; ClinicalTrials.gov search: 'KPV BPC-157 TB-500 GHK-Cu', 0 records).

The KPV human and pigmentation searches appear above; the combination search does not establish a GLOW-only absence.

As of 2026-09-13, no completed study has reported dedicated KPV toxicology covering acute toxicity, repeat-dose testing, genotoxicity or dermal sensitization (PubMed search: '("KPV"[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (toxicology[tiab] OR "LD50"[tiab] OR genotoxicity[tiab] OR "repeated dose"[tiab] OR "repeat-dose"[tiab] OR sensitization[tiab] OR sensitisation[tiab])', 1 hit; ClinicalTrials.gov search: 'KPV', 0 records).

Component-specific absence searches remain in the GHK-Cu and BPC-157/TB-500 articles.

Preclinical KPV data

The doses named here are the arms of the cited studies, not an application protocol for research vials.

Unstated doses and reporting gaps below concern the retrieved abstracts; quoted full-text observations retain their tested material.

Species	Route	Dose and duration as printed	Tolerability or toxicity sentence	Material tested	Source
Mouse, cortical impact	Intraperitoneal	1 mg/kg once, 30 min after injury; 24 h observation; n = 10 per randomized arm	“All animals of primary lesion, sham and vehicle group survived the observation period. In alpha-MSH(11-13) injected group one animal was euthanized before injection of treatment because of persistent seizures after injury” (PMID 23940690). Source prints no attributable rate.	Free KPV	PMID 23940690
Mouse, acute colitis	Intravenous	Free KPV 1 mg/kg per day for 7 days	For KPV/FK506 nanoparticles: “Histological analysis of the main organs revealed no signs of toxicity after 7 days of tail vein injection of NPs, indicating good bio-safety” (PMID 39211778).	Free KPV dose; nanoparticle histology	PMID 39211778
Mouse, acute colitis	Oral gavage	Free KPV 1 mg/kg daily during 7 days	“Daily proKPV administration for 7 days did not induce apparent systemic toxicity, as implicated by histological examination of hematoxylin and eosin (H&E)-stained sections of major organs and GI tissues” describes the proKPV conjugate (PMID 41533788).	Free KPV dose; conjugate histology	PMID 41533788
Mouse, APCMin/+	Oral drinking water	100 micromol/L, ages 5 to 18 weeks (13 weeks)	Tumor endpoint above; no toxicity panel.	Free KPV	PMID 27458604
Rabbit, pyrogen model	Central; peripheral	Central 0.5 to 2.0 mg; peripheral 2 to 200 mg per animal; duration unstated	Abstract prints no toxicity endpoint.	Free KPV	PMID 6333677
Rabbit, corneal abrasion	Topical ocular	1, 5 or 10 mg/mL; 30 microl, two drops four times daily for 4 days	Abstract prints no irritation/tolerability endpoint.	Free KPV	PMID 16965771
Rat, colitis model	Intracolonic	Dose/duration unstated	Abstract prints no adverse-event statement.	Double-network KPV hydrogel	PMID 35245681
Rat, colitis model	Rectal	Dose/duration unstated	Abstract prints no local-tolerance statement.	KPV/SH-PGA hydrogel	PMID 34547895
Rat, oral mucositis	Topical gingival	Adhered for 7 hours after single application	Abstract prints no irritation statement.	KPV@PPP_2%E hydrogel	PMID 34846053
Diabetic mouse, wound model	Topical film	Release within 3 days; dose unstated	Abstract prints no adverse-event statement.	KPV plus EGF film	PMID 36240893
Mouse, vascular calcification	Unstated in abstract	Dose/duration unstated	“good stability and biosafety” describes KPV plus rapamycin nanoparticles (PMID 39252648).	Nanoparticles	PMID 39252648
Animal species unstated	Intracerebroventricular	5.0 pmol once	“5.0 pmol of alpha-MSH-(11-13) alone did not affect food consumption”; not a tolerability endpoint (PMID 1330615).	Free KPV	PMID 1330615
Mouse; intestinal cells	Oral; in vitro	Dose/duration unstated	“NPs (400 nm) did not affect cell viability or barrier functions” describes nanoparticles (PMID 19909746).	Nanoparticles	PMID 19909746
Mouse; intestinal cells	Oral; cell assays	Dose/duration unstated	“nontoxic and biocompatible with intestinal cells” describes hyaluronic-acid-functionalized KPV nanoparticles (PMID 28143741).	Nanoparticles	PMID 28143741
Mouse, colitis model	Oral drinking water	Dose/duration unstated	Abstract prints no toxicity statement.	Free KPV	PMID 18061177
Mouse, colitis model	Unstated in abstract	Dose/duration unstated	Mortality-related efficacy wording supplies neither denominator nor comparator rate.	KPV, formulation unstated	PMID 18092346
Mouse, peritonitis	Systemic	Dose/duration unstated	Abstract prints no adverse-event statement.	Free KPV	PMID 12750433

Mouse, cortical impact

Route: Intraperitoneal
Dose and duration as printed: 1 mg/kg once, 30 min after injury; 24 h observation; n = 10 per randomized arm
Tolerability or toxicity sentence: “All animals of primary lesion, sham and vehicle group survived the observation period. In alpha-MSH(11-13) injected group one animal was euthanized before injection of treatment because of persistent seizures after injury” (PMID 23940690). Source prints no attributable rate.
Material tested: Free KPV
Source: PMID 23940690

Mouse, acute colitis

Route: Intravenous
Dose and duration as printed: Free KPV 1 mg/kg per day for 7 days
Tolerability or toxicity sentence: For KPV/FK506 nanoparticles: “Histological analysis of the main organs revealed no signs of toxicity after 7 days of tail vein injection of NPs, indicating good bio-safety” (PMID 39211778).
Material tested: Free KPV dose; nanoparticle histology
Source: PMID 39211778

Mouse, acute colitis

Route: Oral gavage
Dose and duration as printed: Free KPV 1 mg/kg daily during 7 days
Tolerability or toxicity sentence: “Daily proKPV administration for 7 days did not induce apparent systemic toxicity, as implicated by histological examination of hematoxylin and eosin (H&E)-stained sections of major organs and GI tissues” describes the proKPV conjugate (PMID 41533788).
Material tested: Free KPV dose; conjugate histology
Source: PMID 41533788

Mouse, APCMin/+

Route: Oral drinking water
Dose and duration as printed: 100 micromol/L, ages 5 to 18 weeks (13 weeks)
Tolerability or toxicity sentence: Tumor endpoint above; no toxicity panel.
Material tested: Free KPV
Source: PMID 27458604

Rabbit, pyrogen model

Route: Central; peripheral
Dose and duration as printed: Central 0.5 to 2.0 mg; peripheral 2 to 200 mg per animal; duration unstated
Tolerability or toxicity sentence: Abstract prints no toxicity endpoint.
Material tested: Free KPV
Source: PMID 6333677

Rabbit, corneal abrasion

Route: Topical ocular
Dose and duration as printed: 1, 5 or 10 mg/mL; 30 microl, two drops four times daily for 4 days
Tolerability or toxicity sentence: Abstract prints no irritation/tolerability endpoint.
Material tested: Free KPV
Source: PMID 16965771

Rat, colitis model

Route: Intracolonic
Dose and duration as printed: Dose/duration unstated
Tolerability or toxicity sentence: Abstract prints no adverse-event statement.
Material tested: Double-network KPV hydrogel
Source: PMID 35245681

Rat, colitis model

Route: Rectal
Dose and duration as printed: Dose/duration unstated
Tolerability or toxicity sentence: Abstract prints no local-tolerance statement.
Material tested: KPV/SH-PGA hydrogel
Source: PMID 34547895

Rat, oral mucositis

Route: Topical gingival
Dose and duration as printed: Adhered for 7 hours after single application
Tolerability or toxicity sentence: Abstract prints no irritation statement.
Material tested: KPV@PPP_2%E hydrogel
Source: PMID 34846053

Diabetic mouse, wound model

Route: Topical film
Dose and duration as printed: Release within 3 days; dose unstated
Tolerability or toxicity sentence: Abstract prints no adverse-event statement.
Material tested: KPV plus EGF film
Source: PMID 36240893

Mouse, vascular calcification

Route: Unstated in abstract
Dose and duration as printed: Dose/duration unstated
Tolerability or toxicity sentence: “good stability and biosafety” describes KPV plus rapamycin nanoparticles (PMID 39252648).
Material tested: Nanoparticles
Source: PMID 39252648

Animal species unstated

Route: Intracerebroventricular
Dose and duration as printed: 5.0 pmol once
Tolerability or toxicity sentence: “5.0 pmol of alpha-MSH-(11-13) alone did not affect food consumption”; not a tolerability endpoint (PMID 1330615).
Material tested: Free KPV
Source: PMID 1330615

Mouse; intestinal cells

Route: Oral; in vitro
Dose and duration as printed: Dose/duration unstated
Tolerability or toxicity sentence: “NPs (400 nm) did not affect cell viability or barrier functions” describes nanoparticles (PMID 19909746).
Material tested: Nanoparticles
Source: PMID 19909746

Mouse; intestinal cells

Route: Oral; cell assays
Dose and duration as printed: Dose/duration unstated
Tolerability or toxicity sentence: “nontoxic and biocompatible with intestinal cells” describes hyaluronic-acid-functionalized KPV nanoparticles (PMID 28143741).
Material tested: Nanoparticles
Source: PMID 28143741

Mouse, colitis model

Route: Oral drinking water
Dose and duration as printed: Dose/duration unstated
Tolerability or toxicity sentence: Abstract prints no toxicity statement.
Material tested: Free KPV
Source: PMID 18061177

Mouse, colitis model

Route: Unstated in abstract
Dose and duration as printed: Dose/duration unstated
Tolerability or toxicity sentence: Mortality-related efficacy wording supplies neither denominator nor comparator rate.
Material tested: KPV, formulation unstated
Source: PMID 18092346

Mouse, peritonitis

Route: Systemic
Dose and duration as printed: Dose/duration unstated
Tolerability or toxicity sentence: Abstract prints no adverse-event statement.
Material tested: Free KPV
Source: PMID 12750433

In vitro, the KPV/FK506 nanoparticles “did not induce cytotoxicity” in RAW264.7 macrophages after 24 h (PMID 39211778). The proKPV conjugate showed “low cytotoxicity at concentrations <= 1000 microg/ml” in RAW264.7 macrophages and Caco-2 epithelial cells after 24 hours (PMID 41533788). These are formulation-specific cell assays.

PeptidesDirect does not sell FK506. PeptidesDirect does not sell proKPV. PeptidesDirect does not sell rapamycin.

Conclusions for Research

Corpus mentions measure attention to terms. Component findings retain molecule, formulation and route. Nanoparticle histology does not establish free-KPV toxicology. Component records cannot establish a blend adverse-event profile.

Sources and further reading:

- PMID 16847171: https://pubmed.ncbi.nlm.nih.gov/16847171/

- PMID 30057663: https://pubmed.ncbi.nlm.nih.gov/30057663/

- PMID 29482481: https://pubmed.ncbi.nlm.nih.gov/29482481/

- PMID 40131143: https://pubmed.ncbi.nlm.nih.gov/40131143/

- PMID 39325560: https://pubmed.ncbi.nlm.nih.gov/39325560/

- PMID 22962027: https://pubmed.ncbi.nlm.nih.gov/22962027/

- PMID 34346165: https://pubmed.ncbi.nlm.nih.gov/34346165/

- PMID 39211778: https://pubmed.ncbi.nlm.nih.gov/39211778/

- PMID 41533788: https://pubmed.ncbi.nlm.nih.gov/41533788/

- PMID 22837805: https://pubmed.ncbi.nlm.nih.gov/22837805/

- PMID 9700761: https://pubmed.ncbi.nlm.nih.gov/9700761/

- PMID 10670585: https://pubmed.ncbi.nlm.nih.gov/10670585/

- PMID 27458604: https://pubmed.ncbi.nlm.nih.gov/27458604/

- PMID 2537778: https://pubmed.ncbi.nlm.nih.gov/2537778/

- PMID 23940690: https://pubmed.ncbi.nlm.nih.gov/23940690/

- PMID 36694841: https://pubmed.ncbi.nlm.nih.gov/36694841/

- PMID 6333677: https://pubmed.ncbi.nlm.nih.gov/6333677/

- PMID 16965771: https://pubmed.ncbi.nlm.nih.gov/16965771/

- PMID 35245681: https://pubmed.ncbi.nlm.nih.gov/35245681/

- PMID 34547895: https://pubmed.ncbi.nlm.nih.gov/34547895/

- PMID 34846053: https://pubmed.ncbi.nlm.nih.gov/34846053/

- PMID 36240893: https://pubmed.ncbi.nlm.nih.gov/36240893/

- PMID 39252648: https://pubmed.ncbi.nlm.nih.gov/39252648/

- PMID 1330615: https://pubmed.ncbi.nlm.nih.gov/1330615/

- PMID 19909746: https://pubmed.ncbi.nlm.nih.gov/19909746/

- PMID 28143741: https://pubmed.ncbi.nlm.nih.gov/28143741/

- PMID 18061177: https://pubmed.ncbi.nlm.nih.gov/18061177/

- PMID 18092346: https://pubmed.ncbi.nlm.nih.gov/18092346/

- PMID 12750433: https://pubmed.ncbi.nlm.nih.gov/12750433/

- NCT03937882: https://clinicaltrials.gov/study/NCT03937882

- NCT00832091: https://clinicaltrials.gov/study/NCT00832091

- NCT00382174: https://clinicaltrials.gov/study/NCT00382174

- FDA PCAC briefing: https://www.fda.gov/media/193343/download

- FDA bulk drug substances, withdrawn nominations: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

- CIR safety assessment 2014: https://www.cir-safety.org/sites/default/files/tripep062014final.pdf

- IOM 2001, Copper: https://www.ncbi.nlm.nih.gov/books/NBK222312/

- PubChem CID 23978: https://pubchem.ncbi.nlm.nih.gov/compound/23978; CID 71587328: https://pubchem.ncbi.nlm.nih.gov/compound/71587328

- Product pages, labeled composition, retrieved 2026-09-13: https://api.peptidesdirect.io/products/glow?locale=en; https://api.peptidesdirect.io/products/klow?locale=en; https://api.peptidesdirect.io/products/kpv?locale=en

- Search logs: absence searches dated 2026-09-13, strings and hit counts printed above.

- Reddit corpus: .scratch/reddit-corpus/question-posts.jsonl and .scratch/reddit-corpus/delta-question-posts.jsonl, 12 months, 2025-08-01 to 2026-09-04; .scratch/reddit-corpus/delta2/questions.json, delta, 2026-09-04 to 2026-09-12. Counts: .scratch/paketA/glow/reddit-counts.json, .scratch/paketA/klow/reddit-counts.json, .scratch/paketA/kpv/reddit-counts.json, .scratch/paketA/glow-klow-kpv/reddit-counts.json. Regexes: GLOW \bglow\b(?!\s*(up|ing|y)); KLOW \bklow\b; KPV \bkpv\b; Any \bglow\b(?!\s*(up|ing|y))|\bklow\b|\bkpv\b. Category regexes and 250-character rule: .scratch/paketA/count-reactions.py.

Frequently Asked Questions

Related Products

GLOWregeneration

KLOWregeneration

KPVregeneration

KPV is the C-terminal tripeptide of alpha-MSH, Lys-Pro-Val (positions 11 to 13). Studied in cell and mouse models for NF-kB signalling, PepT1 transport in intestinal cells and antimicrobial activity in vitro. Batch-specific third-party CoA.

This article is for informational purposes only for scientific research.